Amedeo Smart

Free Medical Literature Service

 

Amedeo

Lung Cancer
  Free Subscription

Articles published in
Cancer Sci
    October 2025
  1. TAKAOKA H, Terai H, Nakamura K, Mizuno T, et al
    Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.
    Cancer Sci. 2025;116:2819-2830.
    >> Share

  2. TERASHIMA Y, Park S, Ikeuchi H, Hayashi T, et al
    Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
    Cancer Sci. 2025;116:2868-2881.
    >> Share

  3. NGUYEN TTN, Chen PY, Zheng MY, Lin TK, et al
    Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:2737-2749.
    >> Share

  4. ZHANG Z, Wang C, Guo Y, Zhao Z, et al
    HROB Induces Lung Adenocarcinoma Progression via ZC3HC1-CCNB1 Axis Regulation and Cell Cycle Dysregulation.
    Cancer Sci. 2025;116:2699-2711.
    >> Share

    September 2025
  5. ZENKE Y, Shiraishi Y, Goto Y, Azuma K, et al
    Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Cancer Sci. 2025 Sep 21. doi: 10.1111/cas.70188.
    >> Share

  6. YANG W, Wu X, Cai F, Guo Z, et al
    NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1/CDK1 Pathway and Is a Potential Prognostic Biomarker.
    Cancer Sci. 2025;116:2400-2412.
    >> Share

  7. HORI K, Tanaka I, Sato T, Sato M, et al
    PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma.
    Cancer Sci. 2025;116:2413-2426.
    >> Share

    August 2025
  8. MO X, He J, Shen X, Li C, et al
    Connexin43 Promotes the Invasion and Metastasis of Lung Squamous Cell Carcinoma via GJIC-Dependent Ca(2+)/ERK Signaling Activation.
    Cancer Sci. 2025;116:2086-2100.
    >> Share

  9. YOKOYAMA T, Saitoh M, Miyazawa K
    TGF-beta Enhances Doxorubicin Resistance and Anchorage-Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression.
    Cancer Sci. 2025;116:2176-2188.
    >> Share

  10. KIJIMA T, Kato T, Goto Y, Kuribayashi K, et al
    KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.
    Cancer Sci. 2025;116:2208-2217.
    >> Share

  11. WEI T, Cheng Y, Ge J, Zhu M, et al
    The Pro-Apoptotic Effect of Glucose Restriction in NSCLC via AMPK-Regulated Circadian Clock Gene Bmal1.
    Cancer Sci. 2025;116:2101-2112.
    >> Share

    July 2025
  12. HOSOYA K, Ozasa H, Yoshida H, Ajimizu H, et al
    Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.
    Cancer Sci. 2025;116:1883-1896.
    >> Share

    June 2025
  13. MEN B, Chen Z, Ge H, Yang Z, et al
    Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1.
    Cancer Sci. 2025 Jun 8. doi: 10.1111/cas.70113.
    >> Share

  14. HONGU T, Sarenqiqige, Shandan, Kusunoki H, et al
    Permeable Lung Vasculature Creates Chemoresistant Endothelial Niche by Producing SERPINE1 at Breast Cancer Metastatic Sites.
    Cancer Sci. 2025;116:1604-1615.
    >> Share

  15. ZHANG Y, Xu Y, Jin H, Liu T, et al
    Spatial Heterogeneity of PD-L1 Expression as a Biomarker for Third-Generation EGFR-TKI Response in Advanced EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:1648-1660.
    >> Share

  16. HUANG J, Yuan Y, Guo L, Xia G, et al
    The impact of BTK knockdown on lung adenocarcinoma growth and immune response.
    Cancer Sci. 2025;116:1550-1564.
    >> Share

    May 2025
  17. MIYASHITA Y, Tajima K, Izumi K, Matsumoto N, et al
    Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors.
    Cancer Sci. 2025;116:1392-1404.
    >> Share

  18. MONIWA K, Tokita S, Sumi T, Saijo H, et al
    Loss of Tapasin in Tumors Potentiates T-Cell Recognition and Anti-Tumor Effects of Immune Checkpoint Blockade.
    Cancer Sci. 2025;116:1203-1213.
    >> Share

    April 2025
  19. OCHI T, Fujiki R, Fukuyo M, Rahmutulla B, et al
    Association of Intratumoral Bacterial Abundance With Lung Cancer Prognosis in Chiba University Hospital Cohort.
    Cancer Sci. 2025 Apr 11. doi: 10.1111/cas.70080.
    >> Share

  20. UTSUMI T, Mizuta H, Seto Y, Uchibori K, et al
    AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.
    Cancer Sci. 2025;116:1034-1047.
    >> Share

  21. LI H, Tang C, Zhao P, Zhong R, et al
    Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT-00420) Alone or With Chemotherapy Inhibit the Growth of SCLC.
    Cancer Sci. 2025;116:951-965.
    >> Share

  22. DING J, Wang X, Yang H, Zhang L, et al
    IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.
    Cancer Sci. 2025;116:936-950.
    >> Share

  23. LIU X, Yu D, Yu Z, Su S, et al
    LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.
    Cancer Sci. 2025;116:923-935.
    >> Share

  24. WANG P, Xu J, You W, Li J, et al
    CYP24A1 Binding to FUS Maintains Tumor Properties by Regulating the miR-200c/ZEB1/EMT Axis.
    Cancer Sci. 2025;116:910-922.
    >> Share

    March 2025

  25. Correction to "Celastrol Induces Proteasomal Degradation of FANCD2 to Sensitize Lung Cancer Cells to DNA Crosslinking Agents".
    Cancer Sci. 2025 Mar 29. doi: 10.1111/cas.70066.
    >> Share

  26. SHEN S, Wu Y, Shao Z, Li Y, et al
    LTF as a Potential Predictive Biomarker for Durable Benefit From First-Line Chemo-Immunotherapy in Small Cell Lung Cancer.
    Cancer Sci. 2025 Mar 17. doi: 10.1111/cas.70049.
    >> Share

  27. SAKAMOTO S, Inoue H, Takino T, Kohda Y, et al
    Claudin-11 Enhances Invasive and Metastatic Abilities of Small-Cell Lung Cancer Through MT1-MMP Activation.
    Cancer Sci. 2025 Mar 13. doi: 10.1111/cas.70038.
    >> Share

  28. ZHANG Y, Xu Y, Xu J, Zhong H, et al
    Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.
    Cancer Sci. 2025;116:753-763.
    >> Share

  29. ZHU P, Li Z, Sun Y, Liu T, et al
    Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC.
    Cancer Sci. 2025;116:581-591.
    >> Share

  30. CHEN Y, Pan G, Yang Y, Wu H, et al
    Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.
    Cancer Sci. 2025;116:792-807.
    >> Share

    February 2025
  31. PAN Z, Qian Y, Wang Y, Zhang T, et al
    STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS(G12C) Inhibitors in Nonsmall Cell Lung Cancer.
    Cancer Sci. 2025 Feb 12. doi: 10.1111/cas.70017.
    >> Share

  32. OI H, Taki T, Kuroe T, Sakamoto N, et al
    NETosis in pulmonary pleomorphic carcinoma.
    Cancer Sci. 2025;116:524-532.
    >> Share

    January 2025
  33. WU Y, Cui Y, Zheng X, Yao X, et al
    Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes.
    Cancer Sci. 2025;116:95-111.
    >> Share

    December 2024
  34. ZHAO Z, Bhardwaj M, Fan Z, Li X, et al
    Smoking-independent DNA methylation markers for lung cancer risk: External validation in a large population-based cohort study.
    Cancer Sci. 2024 Dec 3. doi: 10.1111/cas.16414.
    >> Share

  35. IWASAKI T, Shirota H, Sasaki K, Ouchi K, et al
    Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
    Cancer Sci. 2024;115:4034-4044.
    >> Share

    November 2024
  36. KA M, Matsumoto Y, Ando T, Hinata M, et al
    Integrin-alpha5 expression and its role in non-small cell lung cancer progression.
    Cancer Sci. 2024 Nov 24. doi: 10.1111/cas.16416.
    >> Share

  37. SAKAI K, Ohara S, Tanaka J, Suda K, et al
    Improved platelet separation performance from whole blood using an acoustic fluidics system.
    Cancer Sci. 2024;115:3795-3803.
    >> Share

  38. TAKI T, Koike Y, Adachi M, Sakashita S, et al
    A novel histopathological feature of spatial tumor-stroma distribution predicts lung squamous cell carcinoma prognosis.
    Cancer Sci. 2024;115:3804-3816.
    >> Share

    October 2024
  39. XU F, Wang C, Li H, Yu B, et al
    Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.
    Cancer Sci. 2024 Oct 28. doi: 10.1111/cas.16360.
    >> Share

    September 2024
  40. FURUTA M, Horinouchi H, Yokota I, Yamaguchi T, et al
    Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
    Cancer Sci. 2024 Sep 15. doi: 10.1111/cas.16340.
    >> Share

  41. NISHITSUJI K, Mito R, Ikezaki M, Yano H, et al
    Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma.
    Cancer Sci. 2024;115:2947-2960.
    >> Share

    August 2024
  42. WU ZY, Yang DW, He YQ, Wang TM, et al
    Plasma ofCS-modified CD44 predicts the survival of patients with lung cancer.
    Cancer Sci. 2024 Aug 27. doi: 10.1111/cas.16319.
    >> Share

  43. ONDA N, Nakamichi S, Hirao M, Matsuda K, et al
    Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Cancer Sci. 2024;115:2718-2728.
    >> Share

  44. FUJIKAWA Y, Kawabata S, Tsujino K, Yamada H, et al
    Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors.
    Cancer Sci. 2024;115:2774-2785.
    >> Share

  45. SHI Y, Zhang J, Li J, He J, et al
    USP15, activated by TFAP4 transcriptionally, stabilizes SHC1 via deubiquitination and deteriorates renal cell carcinoma.
    Cancer Sci. 2024;115:2617-2629.
    >> Share

  46. LI C, Hu M, Cai S, Yang G, et al
    Dysfunction of CD8(+) T cells around tumor cells leads to occult lymph node metastasis in NSCLC patients.
    Cancer Sci. 2024;115:2528-2539.
    >> Share

    July 2024
  47. AHAMED MT, Forshed J, Levitsky A, Lehtio J, et al
    Multiplex plasma protein assays as a diagnostic tool for lung cancer.
    Cancer Sci. 2024 Jul 30. doi: 10.1111/cas.16300.
    >> Share

  48. MATSUI Y, Yamada T, Katayama Y, Hirai S, et al
    Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
    Cancer Sci. 2024 Jul 22. doi: 10.1111/cas.16292.
    >> Share

  49. WANG Y, Ma L, Chen Y, Yun W, et al
    Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
    Cancer Sci. 2024;115:2184-2195.
    >> Share

    June 2024
  50. SHAO Y, Zhang J, Feng Z, Wu W, et al
    Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.
    Cancer Sci. 2024 Jun 26. doi: 10.1111/cas.16250.
    >> Share

  51. ZHANG C, Yang L, Zhao W, Zhu H, et al
    A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16253.
    >> Share

  52. WANG J, Wang S, Yang H, Wang R, et al
    Methyltransferase like-14 suppresses growth and metastasis of non-small-cell lung cancer by decreasing LINC02747.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16254.
    >> Share

  53. GUO Y, Kasai Y, Tanaka Y, Ohashi-Kumagai Y, et al
    IGSF3 is a homophilic cell adhesion molecule that drives lung metastasis of melanoma by promoting adhesion to vascular endothelium.
    Cancer Sci. 2024;115:1936-1947.
    >> Share

  54. FUKUDA H, Arai K, Mizuno H, Nishito Y, et al
    Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Cancer Sci. 2024;115:1763-1777.
    >> Share

  55. RAUT JR, Bhardwaj M, Schottker B, Holleczek B, et al
    Cancer-specific risk prediction with a serum microRNA signature.
    Cancer Sci. 2024;115:2049-2058.
    >> Share

    May 2024
  56. SHIBA-ISHII A, Takemura N, Kawai H, Matsubara D, et al
    Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms.
    Cancer Sci. 2024 May 27. doi: 10.1111/cas.16192.
    >> Share

  57. DUCH P, Diaz-Valdivia N, Gabasa M, Ikemori R, et al
    Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
    Cancer Sci. 2024;115:1505-1519.
    >> Share

    April 2024
  58. ZHANG C, Sun N, Fei Q, Peng L, et al
    MEN1 deficiency stabilizes PD-L1 and promotes tumor immune evasion of lung cancer.
    Cancer Sci. 2024 Apr 30. doi: 10.1111/cas.16196.
    >> Share

  59. OTANI Y, Katayama H, Zhu Y, Huang R, et al
    Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer.
    Cancer Sci. 2024 Apr 27. doi: 10.1111/cas.16164.
    >> Share

  60. ALANAZI M, Weng T, McLeod L, Gearing LJ, et al
    Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
    Cancer Sci. 2024 Apr 9. doi: 10.1111/cas.16171.
    >> Share

  61. MORISE M, Kato T, Matsumoto S, Inoue T, et al
    Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
    Cancer Sci. 2024;115:1296-1305.
    >> Share

  62. MIZOTE Y, Inoue T, Akazawa T, Kunimasa K, et al
    Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
    Cancer Sci. 2024;115:1114-1128.
    >> Share

    March 2024

  63. Correction to: Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 20. doi: 10.1111/cas.16163.
    >> Share

  64. ISHIDA M, Iwasaku M, Doi T, Ishikawa T, et al
    Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 7. doi: 10.1111/cas.16130.
    >> Share

  65. WANG S, Wang J, Gong W, Zhang F, et al
    ILT4 facilitates angiogenesis in non-small cell lung cancer.
    Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16126.
    >> Share

    February 2024
  66. KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
    Salivary metabolomic biomarkers for non-invasive lung cancer detection.
    Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
    >> Share

  67. KAWAI S, Lin Y, Tsuge H, Ito H, et al
    Body mass index and lung cancer risk: Pooled analysis of 10 prospective cohort studies in Japan.
    Cancer Sci. 2024 Feb 4. doi: 10.1111/cas.16093.
    >> Share

  68. YONEDA H, Mitsuhashi A, Yoshida A, Ogino H, et al
    Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.
    Cancer Sci. 2024;115:357-368.
    >> Share

  69. HASEGAWA S, Shintani Y, Takuwa T, Aoe K, et al
    Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.
    Cancer Sci. 2024;115:507-528.
    >> Share

    January 2024
  70. TSUJI K, Mizugaki H, Yokoo K, Kobayashi M, et al
    Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
    Cancer Sci. 2024 Jan 29. doi: 10.1111/cas.16094.
    >> Share

  71. ZHANG J, Li Y, Yang Y, Huang J, et al
    A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.
    Cancer Sci. 2024;115:109-124.
    >> Share

    December 2023
  72. SHIMOMURA Y, Sawa K, Imai T, Ihara Y, et al
    Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
    Cancer Sci. 2023 Dec 27. doi: 10.1111/cas.16056.
    >> Share

  73. HUANG R, Wu D, Zhang K, Hu G, et al
    ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
    Cancer Sci. 2023 Dec 15. doi: 10.1111/cas.16052.
    >> Share

  74. MITSUDOMI T, Ito H, Okada M, Sugawara S, et al
    Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
    Cancer Sci. 2023 Dec 14. doi: 10.1111/cas.16030.
    >> Share


  75. Correction to Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
    Cancer Sci. 2023 Dec 10. doi: 10.1111/cas.16000.
    >> Share

  76. SUMITOMO R, Menju T, Shimazu Y, Toyazaki T, et al
    M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor beta/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamou
    Cancer Sci. 2023;114:4521-4534.
    >> Share

  77. WANG Q, Song X, Zhao F, Chen Q, et al
    Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram.
    Cancer Sci. 2023;114:4607-4621.
    >> Share

    November 2023
  78. FUJIMOTO K, Matsumoto Y, Imabayashi T, Uchimura K, et al
    Suitability of respiratory endoscopy for sampling malignant thoracic tumors for comprehensive genomic profiling.
    Cancer Sci. 2023;114:4401-4412.
    >> Share

  79. KANG N, Fan B, Sun Y, Xue P, et al
    Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis.
    Cancer Sci. 2023;114:4413-4425.
    >> Share

    October 2023
  80. NAKANISHI T, Yoneshima Y, Okamura K, Yanagihara T, et al
    MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
    Cancer Sci. 2023;114:4101-4113.
    >> Share

    September 2023
  81. HUAI Q, Luo C, Song P, Bie F, et al
    Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
    Cancer Sci. 2023 Sep 20. doi: 10.1111/cas.15964.
    >> Share

  82. ANDO C, Ichihara E, Nishi T, Morita A, et al
    Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
    Cancer Sci. 2023 Sep 15. doi: 10.1111/cas.15958.
    >> Share

  83. HINOKUMA H, Kanamori Y, Ikeda K, Hao L, et al
    Distinct functions between ferrous and ferric iron in lung cancer cell growth.
    Cancer Sci. 2023 Sep 8. doi: 10.1111/cas.15949.
    >> Share

  84. CHEN Y, Jin L, Ma Y, Liu Y, et al
    BACH1 promotes lung adenocarcinoma cell metastasis through transcriptional activation of ITGA2.
    Cancer Sci. 2023;114:3568-3582.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016